GRAIL, Inc. — Investor Relations & Filings

GRAIL, Inc. is a healthcare company dedicated to detecting cancer early. Its mission is to reduce the global burden of cancer through early diagnosis when treatment may be more effective. The company's flagship product is the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The Galleri test is designed to screen for a signal shared by multiple types of cancer, including many that lack recommended screening methods, often before symptoms appear. GRAIL develops its technology by leveraging next-generation sequencing (NGS), machine learning, and data from population-scale clinical studies. The company's focus is on identifying deadly cancers in their initial stages to improve patient outcomes.